HK1206623A1 - Pharmaceutical compositions and treatment of mastitis - Google Patents

Pharmaceutical compositions and treatment of mastitis

Info

Publication number
HK1206623A1
HK1206623A1 HK15107280.7A HK15107280A HK1206623A1 HK 1206623 A1 HK1206623 A1 HK 1206623A1 HK 15107280 A HK15107280 A HK 15107280A HK 1206623 A1 HK1206623 A1 HK 1206623A1
Authority
HK
Hong Kong
Prior art keywords
mastitis
treatment
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HK15107280.7A
Other languages
English (en)
Chinese (zh)
Inventor
Robrecht Froyman
Heinz-Georg Wetzstein
Kristine Fraatz
Wolfgang Wiehl
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of HK1206623A1 publication Critical patent/HK1206623A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15107280.7A 2012-06-29 2015-07-30 Pharmaceutical compositions and treatment of mastitis HK1206623A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666312P 2012-06-29 2012-06-29
PCT/EP2013/063310 WO2014001353A1 (en) 2012-06-29 2013-06-25 Pharmaceutical compositions and treatment of mastitis

Publications (1)

Publication Number Publication Date
HK1206623A1 true HK1206623A1 (en) 2016-01-15

Family

ID=48672650

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107280.7A HK1206623A1 (en) 2012-06-29 2015-07-30 Pharmaceutical compositions and treatment of mastitis

Country Status (22)

Country Link
US (1) US10265330B2 (xx)
EP (1) EP2866812B1 (xx)
JP (1) JP6246804B2 (xx)
KR (1) KR20150030707A (xx)
CN (2) CN104379151A (xx)
AR (1) AR091603A1 (xx)
AU (1) AU2013283375B2 (xx)
BR (1) BR112014031866A2 (xx)
CA (1) CA2877794C (xx)
CL (1) CL2014003503A1 (xx)
CO (1) CO7240376A2 (xx)
CR (1) CR20140594A (xx)
DO (1) DOP2014000300A (xx)
EC (1) ECSP14033371A (xx)
HK (1) HK1206623A1 (xx)
IL (1) IL235768A0 (xx)
MX (1) MX368153B (xx)
NZ (1) NZ702087A (xx)
PE (1) PE20150199A1 (xx)
PH (1) PH12014502864A1 (xx)
RU (1) RU2659430C2 (xx)
WO (1) WO2014001353A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
US8757092B2 (en) 2011-03-22 2014-06-24 Eco-Composites Llc Animal bedding and associated method for preparing the same
PE20150199A1 (es) 2012-06-29 2015-01-31 Bayer Animal Health Gmbh Composiciones farmaceuticas y tratamiento de mastitis
RU2662300C2 (ru) * 2013-02-08 2018-07-25 Луода Фарма Пти Лимитед Способы лечения микробных инфекций, в том числе мастита
CN105189607B (zh) 2013-03-15 2018-06-15 建新公司 胺官能性聚酰胺
WO2015038281A1 (en) 2013-09-16 2015-03-19 Zoetis Llc Assembly for sequentially delivering substances, and associated methods
JP2016088918A (ja) * 2014-11-11 2016-05-23 大山乳業農業協同組合 乳房炎治療・予防用組成物、並びに、乳房炎の治療・予防方法
PT3124016T (pt) * 2015-07-31 2019-12-13 Univ Warszawski Medyczny Composição de emulsão antipsoriática que compreende cefazolina
US10772900B2 (en) * 2016-07-27 2020-09-15 The Trustees Of The University Of Pennsylvania Drug target for treating veterinary infections and methods of using same
US20220378752A1 (en) * 2019-07-11 2022-12-01 Seren Pharmaceuticals Inc. Novel therapeutic agent for prototheca disease
MX2023007631A (es) * 2020-12-24 2023-07-14 Intervet Int Bv Metodos de tratamiento de la mastitis con un compuesto antimicrobiano de ortosomicina.
RU2762088C1 (ru) * 2021-05-05 2021-12-15 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии" (ФГБНУ "ВНИВИПФиТ") Способ лечения мастита у коров
CN113368043A (zh) * 2021-06-11 2021-09-10 吉林大学 一种复方阿莫西林乳房注入剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034099A (en) * 1974-03-29 1977-07-05 The Upjohn Company Compositions and method for treating mastitis in milk animals
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4210635A (en) * 1978-02-15 1980-07-01 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS62129217A (ja) * 1985-12-02 1987-06-11 Fujisawa Pharmaceut Co Ltd 医薬用殺菌組成物
NZ503027A (en) * 1997-07-29 2002-10-25 Kaneka Corp Use of rifamycin derivative for treating mastitis in a domestic animal
WO2005009472A2 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
DE102004054873A1 (de) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CN101744827B (zh) * 2008-12-15 2012-05-30 天津中敖生物科技有限公司 治疗鸡大肠杆菌的药物组合物及其制备方法、应用
US8449916B1 (en) * 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
EP2404601A1 (en) 2010-07-06 2012-01-11 BioAgency AG New drug combinations for the treatment of Malaria
CN101879172B (zh) * 2010-07-13 2012-07-18 杨建彬 头孢噻呋钠复方制剂
EA021846B1 (ru) 2011-05-11 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
PE20150199A1 (es) 2012-06-29 2015-01-31 Bayer Animal Health Gmbh Composiciones farmaceuticas y tratamiento de mastitis

Also Published As

Publication number Publication date
ECSP14033371A (es) 2015-09-30
CR20140594A (es) 2015-02-06
CN104379151A (zh) 2015-02-25
KR20150030707A (ko) 2015-03-20
RU2659430C2 (ru) 2018-07-02
MX368153B (es) 2019-09-20
CO7240376A2 (es) 2015-04-17
IL235768A0 (en) 2015-01-29
JP2015521644A (ja) 2015-07-30
PE20150199A1 (es) 2015-01-31
MX2014015631A (es) 2015-04-09
WO2014001353A1 (en) 2014-01-03
PH12014502864A1 (en) 2015-02-23
CA2877794A1 (en) 2014-01-03
EP2866812B1 (en) 2017-10-04
EP2866812A1 (en) 2015-05-06
CN110522914A (zh) 2019-12-03
AU2013283375B2 (en) 2018-04-26
CL2014003503A1 (es) 2015-05-04
RU2015102562A (ru) 2016-08-20
BR112014031866A2 (pt) 2022-02-01
US10265330B2 (en) 2019-04-23
US20150164926A1 (en) 2015-06-18
NZ702087A (en) 2016-12-23
JP6246804B2 (ja) 2017-12-13
CA2877794C (en) 2020-08-04
AR091603A1 (es) 2015-02-18
AU2013283375A1 (en) 2014-12-18
DOP2014000300A (es) 2015-07-15

Similar Documents

Publication Publication Date Title
HK1255336A1 (zh) 藥物製劑及其製備方法
HK1206623A1 (en) Pharmaceutical compositions and treatment of mastitis
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
IL252566A0 (en) Pharmacy preparations and methods
HK1213798A1 (zh) 治療性化合物和組合物
RS56720B1 (sr) Jedinjenja i kompozicije za lečenje parazitskih oboljenja
EP2819687A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
PL2814463T3 (pl) Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
HK1211213A1 (en) Treatment of diseases involving mucin
HK1203149A1 (en) Novel dosage form and formulation of abediterol
HK1203050A1 (en) Novel dosage and formulation
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
HK1212225A1 (en) Therapeutic formulation and methods of treatment
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
HRP20180781T1 (hr) Farmaceutski pripravak koji sadržava lidipidipin i proces pripreme
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2825184A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same